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1. INTRODUCTION
In May 1988 the Forty-first World Health Assembly committed WHO
to the global eradication of poliomyelitis by the year 2000
(Resolution WHA41.28). Global eradication, as has been achieved
for smallpox, can be defined as the complete and permanent
cessation of the natural transmission of an infectious-disease
agent (32).
The broad objectives of the global poliomyelitis eradication
initiative are to achieve, by the year 2000, no case of clinical
poliomyelitis associated with wild poliovirus, and no wild
poliovirus identified worldwide through sampling of communities
and the environment (1).
Global poliomyelitis eradication will be highly beneficial. Apart
from the huge benefit associated with the control of the
disease —more than 200,000 cases of paralytic poliomyelitis are
estimated to occur each year--, the main cost savings for all
countries, developed as well as developing, would be provided by
abandoning poliomyelitis immunization. In the United States
alone, the expected savings are estimated to be $114 million per
year (14).
However, because of the epidemiological features of
poliomyelitis, all control efforts directed at the disease can be
dropped only when worldwide eradication has been achieved and
certified.
Two of the main problems to solve before global eradication can
be realized are how to implement and maintain a) high-coverage
immunization programs and b) effective surveillance systems all
over the world.
The purpose of this paper is to review the progress and the
remaining problems in these two key areas.
2. BACKGROUND
For many years, poliomyelitis was considered to be primarily a
problem of highly developed countries. In the past 2 0 years,
however, a number of studies have shown that poliomyelitis is a
worldwide problem. The prevalence of lameness due to
poliomyelitis in children in developing countries is on the order
of 5 cases per 1000 population (5,37).
The initiative for the global eradication of poliomyelitis is
being coordinated by the Expanded Program on Immunization (EPI),
established by the World Health Assembly in 1974. One initial
goal of the EPI was to provide immunization services by 1990 to
all the children of the world during the first year of life
against diphtheria, tetanus, pertussis, measles, tuberculosis and
poliomyelitis (14). The WHO has coordinated the immunization
programs, organized vaccine delivery and improved the cold chain
system in its member countries on all continents (29).
In 1974, immunization coverage in developing countries was
estimated to be less than 5 percent with vaccines distributed by
the EPI. According to data reported to the EPI as of August 1991,
83 percent of children were receiving three doses of diphtheria-
pertussis-tetanus (DTP) vaccine and 85 percent were receiving
three doses of trivalent oral poliovirus vaccine (TOPV) in the
first year of life. The EPI estimates that in 1990 immunization
prevented a total of 442,000 cases of paralytic poliomyelitis
(14) . ^
The most promising evidence that poliomyelitis can be eradicated
comes from the Americas. In May 1985, the Pan American Health
Organization adopted the goal of eradicating the indigenous
transmission of wild-type poliovirus in the Americas by 1990. In
the first 38 weeks of 1991, only seven cases of poliomyelitis in
Latin America were confirmed —six in Colombia and one in Peru
(14). Current trends indicate that the entire Western Hemisphere
may soon be free of indigenously transmitted paralytic
poliomyelitis (27).
Circulation of poliomyelitis worldwide has probably decreased
also. In 1990, 113 countries reported zero cases of poliomyelitis
compared with 74 countries in 1985. This was accompanied by a
decrease in the number of countries reporting more than 10 cases
per year (64 in 1985, 44 in 1989 and 26 in 1990) (43).
Endemic poliomyelitis at the end of 1980s is restricted to
developing countries in Asia and Africa, but, according to WHO,
it is still responsible for more than 200,000 new paralytic cases
annually (29).
3. IMMUNIZATION COVERAGE
3.1. Progress in increasing immunization coverage..
As a guide for planning, four stages in the progress of a country
towards eradication have been devised. These stages reflect the
status of the overall EPI and its ability to undertake special
poliomyelitis activities (1):
Stage A. The country has a reliable reporting system, has
reported no indigenous case of poliomyelitis for the last 3 years
and has achieved polio immunization coverage of 80% or higher.
Stage B. The country has reported fewer than 10 cases per year
for the last 3 years and has achieved polio immunization coverage
of 50% or higher.
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stage C. The country has reported 10 or more cases of
poliomyelitis per year and polio immunization coverage is 50% or
higher.
Stage D. There are 10 or more cases of poliomyelitis per year or
the number is unknown, and polio immunization coverage is less
than 50%, or is unknown.
As of the end of 1990, most (68 percent) of the world's
population lived in areas considered to be in stage C. Twenty-
four percent were living in areas considered to be in stage A or
B, and 8 percent were living in areas considered to be in stage D
(14) (cf. annex 2).
Of the 18 countries/areas with 0PV3 coverage of less than 50% and
with a high risk of poliomyelitis, 14 (78%) are in the African
Region (43). It is not surprising that regions with the highest
incidence of poliomyelitis and the lowest coverage of anti-polio
immunizations coincide with regions having poverty and deficient
organization of the primary health care system (29).
3.2. Poliomyelitis eradication: required immunization coverage.
The immediate target of EPI is to achieve a minimum of 8 0 percent
vaccine coverage among infants by their first birthday in each
district in all countries (44). Based on the experience in
developed countries, the administration of polio vaccine to a
high proportion of children under one year of age will be the
most crucial step in the initial phases of eradication (5). The
exact level of coverage needed is unknown but is certainly in
excess of 80%. Countries in which poliomyelitis has been
eliminated have typically achieved coverage on the order of 90%
(5). Interrupting the transmission of wild poliovirus may require
coverage levels in excess of 80 percent especially in areas of
high population density (1) and where environmental sanitation is
not good (32).
Most epidemic models suggest that when a high enough proportion
of immunes is reached, herd immunity will protect the remaining
susceptibles. Although the exact level of immunity required is
not known, it is clear that the greater the level of
susceptibility, the more likely that epidemic (or endemic)
transmission might be established (23). Futhermore, the risk of
transmission may increase by the coincidence of areas of lower
coverage (e.g, in inner cities) with areas of higher exposure to
wild poliovirus (23).
Poliomyelitis outbreaks have been reported from different areas
in the world where immunization coverage levels were formerly
regarded as sufficient. Several incidents in the "relatively
polio-free regions" indicate the ease with which the apparently
good vaccine-induced "herd immunity" can be disturbed (29). In
1978 more than 100 patients fell ill with poliomyelitis in the
Netherlands. All patients belonged to a religious sect that had
refused all vaccinations. However, the wild type 1 poliovirus
responsible for this outbreak also spread to the vaccinated
"normal" population. Furthermore, through overseas contacts
between members of the sect, the same genotype of type 1
poliovirus spread to the USA and Canada and gave rise to cases of
paralytic poliomyelitis in these countries as well (29) .
An outbreak comprising 9 paralytic cases and at least 100,000
infected persons in a vaccinated population took place in Finland
in 1984-1985. The type 3 poliovirus circulated widely in the
population and was apparently able to select persons who had
remained unvaccinated (29).
In 1988 an outbreak of poliomyelitis involving 16 cases and
caused by a type 1 virus occurred in Israel (29).
In these three situations, a high immunization coverage did not
prevent wild poliovirus from spreading in the community. Several
factors may have contributed to these outbreaks, these are: a)
the exclusive use of inactivated poliovirus vaccine (IPV) which
does not confer intestinal immunity (29), b) the relatively weak
immunogenicity of the IPV preparation used (29), c) the antigenic
difference of the epidemic strain from the type 3 strain in IPV
(29), and d) the identification of specific subpopulations as
reservoirs of infection.
Incidents occurred also with Oral Polio Vaccine (OPV)-immunized
populations. In the West Bank and Gaza, during the 1970s,
immunization using live TOPV covered more than 90% of the infant
population. Nevertheless, the incidence of paralytic polio
continued to be high (9). In Taiwan, an epidemic involving more
than 1,000 paralytic patients occurred in 1982 (29). These
episodes as well as the more recent one in Gambia indicate that
an overall OPV coverage of 80% does not necessary protect the
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population from outbreaks of poliomyelitis. Apparently, pockets
of lower coverage of immunization can maintain the circulation of
wild strains of poliovirus (29). Other factors may contribute to
the persistance of wild polioviruses in community (c.f. 3.5.).
Although these incidents have important implications for the
WHO'S initiative to eradicate poliomyelitis globally, it is clear
that a) maintaining OPV coverage to greater than 80% by 1 year of
age is essential in countries that have substantially reduced or
eliminated wild poliovirus infection (10,18), and b) raising and
maintaining OPV coverage to this level or higher is the most
important strategy to control poliomyelitis in the countries
where the disease is still endemic.
3.3. Strategies of immunization coverage.
High immunization coverage can be achieved by different
strategies. It may be accomplished through strong emphasis on
routine administration of TOPV vaccine by the permanent health
services and through the observance of national "immunization
days" twice a year, one month apart. Mobile strategy
(immunization in villages by mobile teams) is another effective
complement (18); it is sometimes used in countries where the
health care structure density is particularly low. In countries
where effective surveillance identifies fewer than 50 cases of
poliomyelitis per year, house-to-house immunization—so called
mopping-up immunization—is an important part of prompt
intervention in areas where cases are identified (14).
Routine immunization.
The dose at birth, also called "OPV zero" is particularly
important in cities and in other areas with high population
density (1). TOPV is the recommended vaccine because of its low
cost, ease of administration, superiority in conferring
intestinal immunity, and ability to infect household and
community contacts, thus extending vaccine coverage.
Programmes employing routine immunization schedules have already
brought about dramatic reductions in paralytic poliomyelitis in
several developing countries (5). Furthermore, these programmes
are an integral part of, and strengthen, basic health services.
This support is particularly important in most of the poorer
countries where major mortality from measles, malaria,
gastroenteritis, pertussis and tetanus still exists. Because the
vaccine is delivered as part of the MCH services, a greater
continuity of follow-up is assured, and all the MCH activities
benefit. At the same time, the integration of immunization into
the primary health-care services increases their acceptability
and use by the community and opens the way to progress in the
other elements of care, including environmental sanitation (33).
However, improvements in health-care services are often slow and,
in many developing countries, routine health services have been
shown so far to be inadequate to achieve satisfactorily high
level of vaccine coverage. Therefore, a special strategy,
specifically, the use of National Vaccination Days has evolved.
The most dramatic example of this approach has been in Brazil
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(5).
National Vaccination Days,
In the late 1970s it became apparent that routine health services
in Brazil would not be adequate to meet the goal of EPI.
Consequently, it was decided to embark on an accelerated strategy
through the use of national vaccination days: two per year at
least 4 weeks apart, to vaccinate as many children younger than 5
years of age as possible, regardless of their vaccination status
(16). These activities were proposed to supplement the routine
immunization program through regular health services. After 4
years of highly successful efforts against polio, diphtheria-
pertussis-tetanus toxoids and measles vaccine were added to the
national vaccination day in most parts of the country in 1984
(16). Since 1984, all polio endemic countries in the western
hemisphere have successfully adopted this strategy (16). A
similar, but more regional approach called "pulse" immunization
has also proved to be successful in India (5).
It is not known yet if the National Vaccination Days strategy is
successfully exportable to African countries. Cultural
particularities, logistic issues, and the existance of conflict
zones should be taken into account when establishing suitable
immunization coverage programs.
It is important that immunization campaigns be always carefully
articulated to health-care services and be considered as a
temporary immunization strategy. Dr. R. Henderson of the World
Health Organization expressed concern that large, intensive, short-
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lived campaigns could drain the resources and the attention
of the authorities and the public from the less glamourous, but
in the long run necessary, sustained health program (37).
According to Robinson (33), the campaign approach, as a long-term
strategy ,may be politically unattractive, administratively
difficult, and economically extravagant. Furthermore, the success
of the campaign strategy could decrease after some years because
the public attitude toward vaccines in those countries where they
have been most successful is often one of apathy (33).
3.4. Immunization coverage costs and political will.
The Global Poliomyelitis Eradication Program is currently facing
two major issues: an increase in the estimated costs of
eradication and a stagnation in the partners' political will.
In 1988, the World Health Organization estimated the total cost
of the global eradication effort from 1989 to 2000 to be $155
million more than the amount needed for routine activities of the
EPI (14). In the light of the experience in the Americas, these
estimates are being revised. Depending on the quantities of polio
vaccine required in excess of the routinely scheduled doses, the
total cost may be as much as 10-fold higher (14). It is important
to add the qualification that the estimates do not include the
cost of sustaining high levels of immunization coverage in
developing countries. These latter costs total some $ 1 billion
per year and are borne in large part by the developing countries
themselves, particularly the costs of personnel (14).
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Furthermore, since experience showed that poliovirus could
successfully infect unvaccinated individuals in the face of OPV
immunization levels in the general community of approximately 80%
(Taiwan, 1982), higher immunization levels could be needed in
order to interrupt wild poliovirus transmission. The cost of this
increase in coverage will probably be high because one percent of
coverage gained above 80% is much more expensive than one percent
gained around 50%. This is because special strategies are
necessary to reach the last fraction of the population once high
levels of coverage are achieved.
Economic and social research is also needed to provide
information on costs, and to provide the means to understand how
best to design and implement control programmes and identify and
overcome obstacles to their effectiveness (28).
According to Creese (34), there are just three potential sources
of increased economic support for immunization: domestic economic
growth, a shift in priorities for domestic expenditure and
foreign aid.
Economic growth will occur in some developing countries, and some
of it will allow an expansion of primary health care, but the
poorest countries are likely to experience little if any real
growth of per capita income in the next decade (34) . Per capita
income of the 4 0 poorest countries has declined over the past
five years and the percentage of national budgets spent on health
has been unchanged or has diminished for eight years (28).
The second source of funds, domestic expenditure priority shift,
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is unlikely because polio immunization alone is not apriori the
top priority for increased resource allocation in most developing
countries. There has been a scaling exercise in which
poliomyelitis was assessed together with a long list of other
disease problems. In 1981, the Ghana Health Assessment Project
Team ranked 48 disease problems in that country in terms of
economic burden (34). Their calculations took account of
estimated incidence, case fatality rate, age at death, and level
and permanence of disability for each disease. Overall,
poliomyelitis in Ghana ranked 3 3rd of the 48 diseases considered
(34). Malaria and measles were at the top; and tuberculosis,
neonatal and adult tetanus, typhoid, and pertussis were all in
the top 25.
It should be added that since the time of this study, several new
public health problems have tended to drain the resources and the
attention of the authorities. Among them are the resurgence of
cholera, the increasing incidence of sexually transmitted disease
and the appearance of the AIDS pandemic.
Foreign aid clearly favors immunization, doubtless partly because
of the visibility of its results (34). However, in international
organizations, there is a great amount of competition among the
existing health programs for the limited public health resources
available (32). These resources are limited for a variety of
reasons, including the fact that aid contributions of the
goverments of industrialized countries to global development are
well below the amounts previously promised (0.7% of the National
Product).
li
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Recently, however, other sources of financial aid have helped
off-set the shortfall in aid from governmental sources. By 1988,
Rotary International, had raised over US$ 219,000,000 in support
of poliomyelitis eradication. Rotary has provided over 82 nations
with financial aid for vaccine programs, in addition to
participating directly in local immunization campaigns (27).
3.5. Does coverage mean protection?
As immunization coverage levels improve, it will be increasingly
important to evaluate the efficacy of TOPV and the immunization
schedules currently in use. Although the protection conferred by
immunization is very high under optimal conditions, it seems to
be influenced by different factors such as: choice of vaccine,
use in developing countries, vaccine thermolability and quality
of the cold chain, dosage of vaccine, optimal intervals between
doses, and fidelity to the recommended immunization schedule.
Both IPV (inactivated poliovirus vaccine) and OPV (oral
poliovirus vaccine) have been successful in controlling
poliomyelitis in the USA and other developed countries. A primary
series of either IPV or OPV generally induces seroconversion
against all three virus types in more than 90% of recipients.
Available evidence indicates that the resultant clinical
protection is long-lasting, and probably lifelong (5). However
OPV offers two important advantages over IPV: a) it can spread to
close contacts of the vaccinee--virtually all OPV recipients
excrete vaccine virus—, thereby extending protection, and b) it
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often induces local intestinal immunity, which impedes the
ability of the recipient to spread wild poliovirus on subsequent
exposure (5). The mucosal immunity obtained by parenteral
immunization with killed virus is far below that following
poliovirus infection, whether natural or OPV-derived (29). Some
investigators have suggested that IPV might also be able to
induce a good mucosal immunity, because polio-specific secretory
IgA is detected in saliva and breast milk. However, IgA is
probably only a part of the system responsible for the
elimination of poliomyelitis from the body (29). Thus, OPV is
more effective than IPV in limiting wild virus transmission; it
can compete with wild poliovirus for circulation whereas IPV can
not compete in this way (23).
Using decision analysis, Hinman (23) calculated that more
susceptibles would be present in USA if IPV was used. Because of
lack of "extended protection", more cases of paralytic
poliomyelitis would result (74.1 vs 10.0 cases per year) (23).
With the OPV alternative, most cases would be associated with
vaccine, whereas under the IPV model virtually all cases would be
due to wild virus (23).
On the other hand, a combined schedule of OPV and IPV is also
being used or considered in some countries, particularly in view
of the success of the strategy in the Gaza strip (5,9). The
combined use of IPV and OPV is probably a perfect combination,
since OPV confers a good mucosal immunity and IPV results in
seroconversion to all three serotypes. However, the relatively
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high price of this program will certainly delay its wide
acceptance (29). The cost of IPV remains relatively high
(approximately 3 0 times that of OPV), and its administration
reguires more highly trained personnel than does OPV (5).
While OPV has been highly effective in industrialized countries,
its performance in some developing countries has been
considerably lower than expected (5,14,19,27,28), Several
instances of failure to seroconvert after receipt of three doses
have been reported. The rates of seroconversion are suboptimal.
Thirty-two studies in 15 developing countries evaluated the
response of 2 0 or more children to TOPV as formulated by World
Health Organization. There was wide variation in the percentage
of seroconversion, with mean rates of only 73 % (range, 36%-99%)
for poliovirus type 1, 90 % (range, 7l%-99%) for type 2 and 70 %
(range, 40%-99%) for type 3 (14,27). Outbreaks related in part to
such circumstances occurred in north-east Brazil and the Gambia
in 1986. They occurred also in Taiwan (1982) and Oman (1987) in
spite of successful immunization programs (5,18).
Different factors may contribute to the low immunogenicity of OPV
in tropical developing countries, and these are discussed below.
a) Vaccine potency.
There is a discrepancy between the potency of the vaccines used
in the United States and those used in other countries (19). The
requirements set forth by the Expert Committee on Biologic
Standardization, WHO, are that each dose of TOPV contain, at
minimum, 10exp6 50% tissue culture infectious doses (TCID50) of
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type 1, 10exp5 of type 2, and 10exp5.5 of type 3, with a titer
95% confidence limit within +/- 0.5 log unit. Lots prepared for
the use of EPI in many countries meet but do not greatly exceed
the minimum WHO standard. The manufacturer for the United States
routinely exceeds the minimum requirement by at least 0.6 logs. A
recent potency test showed a increased potency of 3 00%, 2 50%, and
700%, for types 1, 2, and 3, respectively, compared with the TOPV
used in the EPI (19). This discrepancy in potency may sometimes
contribute to the lower rate of seroconversion in developing
countries.  However, somewhat contradictory evidence was reported
by investigators in India, where there was no improvement in
immunogenicity with a twofold increase in dose (19).
b) Vaccine formulation.
It was recognized very early in the development of live
attenuated vaccines that the three independently derived Sabin
types had different growth characteristics. Specifically, type 2,
when administered in conjunction with types 1 and 3, tended to
exclude infection by the other types (19). "Balanced"
formulations were later developed as a means of compensation for
these differences and were shown to effectively increase rates of
seroconversion to types 1 and 3 (19). The "balanced" 10:1:3
formulation has been successful in industrialized countries but
may be not optimal for developing countries. Changes in the
ratios of the three components may prove to be an effective way
of enhancing the immunogenicity of TOPV, particularly of type 3
(19).
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c) Vaccine stability.
TOPV is the most thermally labile of all vaccines used in the EPI
and is chemically stabilized with magnesium chloride or sucrose
to minimize losses in potency when exposed to high ambient
temperatures. Studies simulating actual field conditions indicate
that the overall potency of TOPV is reduced by as much as 0.5
logs after storage at 41°C for 1 day (19). Breaks in the cold
chain and suboptimal practices of vaccine handling have been the
most common reasons cited for failure in tropical areas (13,19).
However, improved training and supervision of EPI staff, coupled
with rapid technologic advances in ensuring proper storage
temperatures for TOPV have led to fewer documented failures of
the cold chain over the past decade (19). Furthermore, relatively
low rates of seroconversion have been reported in spite of
optimal conditions for vaccine handling (19).
d) Interval between doses.
Studies of excretion patterns of vaccine virus following
administration of monovalent and trivalent OPV indicate that
excretion can occur for up to three months, with a median of 21
days. Because of interference among the three components of TOPV,
it is likely that continued excretion of virus could interfere
with the response to subsequent doses (19). Data from developing
countries suggest that the 4-week interval between doses
recommended by EPI may play some role in suboptimal
seroconversion rates (19). Studies are being undertaken by the
EPI to determine the optimal interval between doses (14).
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e) Adherence to the recommended immunization schedule.
In countries with endemic poliomyelitis, EPI recommends that TOPV
should be administered at birth and at 6, 10, and 14 weeks of age
(14).
Reported immunization coverage data are sometimes based on the
number of delivered doses without taking into account the date or
schedule of vaccine administration. All children having received
three doses of OPV are considered covered. However, the
recommended immunization schedule, and particularly the intervals
between doses, may not be fully respected. This situation
combined with the suspicion that the recommended 4-week interval
may be too short and hence sub-optimal may partly explain low
responses in some developing countries.
This author and his colleagues conducted an immunization coverage
survey in a rural African district in October-November 1990,
using the standard procedure recommended by WHO (unpublished
data). A sample of thirty clusters of 7 infants from 12 to 23
months of age had been randomly selected from throughout the
district and visited. Coverage data, including the date of each
vaccine administration were collected only from health charts.
The results indicated that 70.5 percent of the children had
received the 8 doses recommended against the 6 EPI diseases (cf
annex 3,4). However, if the EPI vaccine schedule is taken into
consideration, only 51 percent of the children were correctly
immunized, and only 4 0 percent were correctly immunized before 1
year of age. Twenty-eight of the 161 children "completely"
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immunized against polio (17%) were vaccinated incorrectly with
respect to date. The number of incorrect immunizations was higher
for polio vaccine (28) than for the others (DTP:24; Measles:23)
(cf annex 5).
Similar discrepancies between the percentages of children
"completely" versus "correctly" immunized were found in an other
province. Such failure to adhere to immunization schedule may
contribute to suboptimal OPV immunogenicity in developing
countries. Intense training and supervision of the health workers
could increase dramatically the performance of the program.
Furthermore, it would be highly cost-beneficial since vaccines,
cold chain and public confidence and motivation are already
acguired (cf annex 6).
This survey also indicates that 10 percent of the children on at
least one occasion received a DTP dose without polio dose. The
most  reported reason was shortage of polio vaccine. Data
analyses showed that when a polio dose is missed but a DTP dose
is administered, there is a 60% chance that the polio dose will
never be (correctly) given. These findings suggest that improved
management of polio vaccines could easily contribute to increased
immunization coverage.
Another finding of this survey was that an appreciable proportion
of the children could be immunized earlier in the first year of
life (cf annex 7). Only twenty five percent of the children are
completely immunized against polio before the age of 20 weeks, 50
percent before the age of 3 0 weeks and 7 5 percent before the age
lo
of 1 year.
SURVEILLANCE
In addition to achieving and maintaining high immunization
levels, the development of effective surveillance systems for
wild type viruses in the population and community will be
critical. Such systems are essential to define the extent of the
problem and to guide control efforts (5). Standard techniques
will be needed to survey for the wild poliovirus in the
environment, and once the disease is under control, to establish
the absence of virus  circulation.
4.1. Disease surveillance.
To obtain critical information on poliomyelitis, the surveillance
system should involve all institutions and medical-care providers
who are likely to see suspected cases of poliomyelitis, and
involve regular (including negative) reporting from each site
(5).
As a result of EPI's increased emphasis on the timely and
complete collection of data, reporting of poliomyelitis cases has
improved at the global level, as well as in many individual
countries (43). In October 1991, 100% of countries reported 1990
data in 3 WHO Regions (the Region of the Americas, the European
Region and the South-East Asia Region). Reporting completeness
improved in the remaining 3 Regions: 62% of countries in the
African Region, 83% of countries in the Eastern Mediterranean
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Region and 97% of countries in the Western Pacific Region (43).
Although countries pursuing a goal of eradication are building
active surveillance systems for poliomyelitis cases, most
countries still rely on passive surveillance systems. Passive
systems are likely to detect only a small fraction (sometimes
less than 10%) of the cases that occur (43).
In the Americas, however, the development of effective
surveillance systems has permitted strategies for control to
evolve in response to changes in needs. At present, 80 percent of
the nearly 20,000 health facilities in the regional system of
poliomyelitis surveillance are reporting weekly on the presence
or absence of flaccid paralysis (14). Uniform case definitions
have been adopted by all countries of the region.
Case definition:
A clear case definition of poliomyelitis is essential for
surveillance. For reporting purposes, EPI suggested the
following:
A case of poliomyelitis is defined as any patient with acute
flaccid paralysis (including any child less than 15 years of age
diagnosed with Guillain-Barre syndrome) for which no other cause
can be identified.
However, other conditions can cause paralysis and can be confused
with poliomyelitis. Some infections due to other enteroviruses
have the capability to mimic poliomyelitis. An epidemic of seven
hundred and five cases due to enterovirus 71 occurred in Bulgaria
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in 1975. Symptoms observed included gastroenteritis, aseptic
meningitis, encephalitis,and myelitis with 149 cases of paralysis
and 44 deaths (37). Enterovirus 70 and coxsackie viruses A7, Bl,
and B5 have also been implicated in acute flaccid paralysis.
Because acute flaccid paralysis has multiple causes, laboratory-
based surveillance systems must also be developed, at least on a
regional basis, in addition to the clinically and
epidemiologically based system (5,22).
Laboratory isolation.
Laboratory isolation of wild poliovirus from the stools of
children with AFP is necessary for confirmation of wild
poliovirus transmission (22). Established techniques for the
diagnosis and surveillance of poliovirus infections rest entirely
on cell culture isolation of virus (27). It should be possible to
develop modern solid-phase immunoassays for diagnosis of past and
recent poliovirus infections. Solid-phase immunoassays have the
potential to be both inexpensive and suitable for use by
minimally trained individuals in the field (27). Presently, the
recommended approach is to send specimens by cold chain to the
closest reference laboratory. The method for sampling and
shipping is explained in the Manual for the Virological
Investigation of Poliomyelitis published by the World Health
Organization. ,
In the Americas, about 80 percent of the patients with reported
cases are being seen by trained epidemiologists who collect two
stool specimens from each patient and one specimen from each of
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five contacts. In 12 months in 1991, stool sample from 1860
patients with flaccid paralysis were submitted to a network of
eight laboratories for poliovirus isolation (14). During 1991,
only nine AFP cases out of over 2 000 reported cases of AFP were
confirmed by culture as poliomyelitis caused by wild-type
poliovirus (22).
According to Sabin, The extensive use by PAHO of highly
sophisticated regional virus laboratories has led to the
recognition that, in areas from which poliomyelitis caused by
polioviruses has been largely eliminated, there are thousands of
cases of acute flaccid paralysis, previously clinically diagnosed
as "probable poliomyelitis", that have no viral etiology (40).
The maintenance of such a laboratory network requires trained
staff, a reliable transport system, and laboratories with
reliable diagnostic capabilities (14).
4.2. Molecular epidemiological surveillance.
Because a high proportion (>99%) of poliovirus infections are
subclinical, the standard epidemiologic techniques of case-
contact investigations are often unable to reveal the origins of
wild viruses. Molecular methods, based primarily on comparison of
poliovirus genomic sequences, and the recognition that genetic
relatedness implies epidemiologic linkage, offer a powerful,
independent approach for epidemiologic surveillance (6,10).
Poliovirus genomes experience rapid variation upon replication in
humans. The average rate of fixation of mutations over the entire
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genome is about one to two nucleotide substitutions per week ,
and most of these mutations are fixed cumulatively (6,10). The
extent of sequence divergence between related wild poliovirus
isolates provides an approximate measure of the number of
intervening infections separating the cases (10). Furthermore,
epidemicity could be distinguished from endemicity by measuring
the extent of sequence heterogeneity among contemporary isolates
within a country or region (10,41).
Three methods are used for characterizing poliovirus isolates and
they are summarized below.
1. Genomic Sequencing.
Comparisons of selected genomic regions, representing as little
as 2% of the total RNA, provide detailed information on the
genetic relationships among polioviruses. The VP1/2A (90
nucleotides from VPl, 60 from 2A) region has been selected for
poliovirus partial genomic sequencing (10).
2. Oligonucleotide Fingerprinting.
Fingerprints are usually produced by digestion of the viral RNA
with ribonuclease Tl, and electrophoretic separation of the
resulting fragments. This resolves into patterns of spots highly
characteristic for each RNA sequence (10).
3. DNA Probe Hybridization.
This is a rapid and simpler method for determining sequence
homologies within defined genomic intervals, but one should know
in advance the genotypes that may be present (10,29). It is
ͣIS
likely that probe hybridization in combination with polymerase
chain reaction (PCR) will find wide application in virus
diagnostics (10). PCR may achieve highly sensitive detection of
specific viral genomic sequences.
Recently, genomic analysis indicated that the poliovirus
responsible for a large outbreak in a developing country with
high immunization coverage was an imported and not an indigenous
poliovirus strain (Oman 1989) (18). This incident highlights the
need for maintenance of high immunization levels and surveillance
for poliomyelitis, even in countries that have substantially
reduced or eliminated wild poliovirus infection (18).
4.3. Environmental surveillance.
4.3.1. Polioviruses in the environment.
Numerous studies have readily demonstrated the presence of
polioviruses in sewage. Polioviruses multiply primarily in the
alimentary tract and are excreted in substantial amounts (as many
as lOexplO per gram of feces) for varying periods of time, with a
mean shedding period of up to 50 days (39). At present in
countries in which live poliovirus is widely used, the excreted
polioviruses are usually vaccine-derived (39).
Polioviruses, like other enteroviruses, survive relatively well
outside the human body. There is circumstantial evidence
suggesting survival for several months or even years in sewage,
at least in temperate climates (4,29). Recent studies also
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demonstrated that enteroviruses may migrate through soils and
possibly contaminate groundwater supplies (12). Recently,
enteroviruses were recovered from wells located as much as 67 m
down gradient from a domestic subsurface wastwater treatment
systems, indicating extensive migration of enteric viruses in
soil (12) .
Different factors may influence virus survival in the
environment. The effects of these factors are as follows.
a) Temperature. '
Temperature has a considerable influence on virus inactivation
rates in the environment. The survival times of viruses are
shorter at high temperature. Thus, viruses are likely to persist
longer in the environment during the colder months of the year
(12). For example, the period of time for 99% inactivation of
poliovirus type 1 from septic tank affluent in a sand type soil
has been reported to be approximately 416 days at 1-8°C versus 27
days at 20-25°C (12).
b) Soil moisture.
Soil moisture also influences virus survival in soils. Authors
have reported more rapid virus inactivation in dried than in wet
soils. Poliovirus type 1 inactivation was considerably more rapid
in drying soil as the moisture content decreased from 13 to 0.6%
than in the same soil type maintained at 15 or 25% moisture
content. Inactivation of 99% of the initial viruses occurred
within 1 week in drying soil but took 7 to 8 and 10 to 11 weeks
in soils with 25 and 15% moisture content, respectively (12).
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c) Soil microbial activity and related chemical activity.
Soil microbial activity and perhaps related chemical activity due
to microbial enzymes and other chemicals appear to decrease virus
survival in the environment (12). In studies by Sobsey et al.(ll)
on rates of poliovirus inactivation in eight different soil
suspensions in settled sewage at 20°C, the time required for 99%
inactivation was almost always shorter in nonsterile than in
sterile suspensions. A temperature effect on microbially mediated
antiviral activity also was reported (12).
d) Effects of ionic salts and pH.
Direct effects of different pH and salt levels on virus survival
in aqueous solutions have been reported, and similar phenomena
may occur in the soil environment (12). Poliovirus type 1 was
inactivated more rapidly at the pH extremes of 3 and 9 than at
the intermediate pH levels of 5 and 7. Virus inactivation rates
also increased with increasing concentration of NaCl, and the
effect was most pronounced at pH 3 (12).
e) Soil type, virus association with soils, and virus
aggregation.
The association of viruses with soil particles enhance or reduce
their survival, depending on the chemical properties of the soil
material. A number of investigators have observed that virus
absorption to soil particles prolongs their survival (12).
Recently, poliovirus 1 has been found to survive up to 19 days in
seawater with sediments or suspended solids added, while no virus
was detected after 9 days in seawater without particulate matter
22
(12).
Virus aggregation tends to enhance the survival of viruses
exposed to various antiviral agents, and this phenomenon has been
extensively studied in chemically defined solutions containing
purified virions and known quantities of specific disinfectants.
The results of studies in water showed that virus aggregates
survive better than dispersed viruses (12).
4.3.2. Role of polioviruses surveillance.
The detection of poliovirus in sewage has been successfully used
to monitor virus excretion during outbreaks and vaccination
campaigns (29). During an outbreak of paralytic poliomyelitis in
Finland in 1984 and 1985 the widespread circulation of the
causative wild-type serotype 3 poliovirus in the population was
documented by demonstrating the virus in water specimens (4).
Sewage water analysis also turned out to be a useful tool in
evaluating the efficacy of a nationwide vaccination campaign with
oral poliovirus vaccine (4). The efficacy of the vaccination
campaign in regard to elimination of the epidemic type 3 strain
was evaluated by a follow up study on viruses in sewage waters
which continued for 12 months through the subsequent expected
season of poliomyelitis. Several types of enteroviruses,
including five vaccine-related poliovirus strains, were
identified in the 72 virus-positive specimens out of 93 studied.
No wild-type polioviruses were found, indicating the success of
the campaign (4).
26
--?*tc- V*'*^'^'
Prior to the widespread use of OPV, routine screening of sewage
for poliovirus during nonepidemic periods has also been
considered a useful tool to detect an emerging outbreak (29).
However, in spite of the fact that polioviruses are detected in
high numbers in sewage and sewage-polluted waters, poliomyelitis
outbreaks attributed to polluted water have been very rare. A
total of eight outbreaks in Europe and North America had been
reported, but only one of them was adequately documented. This
occurred in Huskerville, Nebraska in 1952 at which time at least
45 became ill after contamination of the local water system (39).
At advanced stages of poliomyelitis control, when vaccine
coverages are high, very few wild poliovirus infections may
result in paralytic cases. Under these conditions, standard case
surveillance and characterization of clinical isolates may not be
sufficiently sensitive to detect continued circulation of wild
poliovirus (10). It may be possible, through environmental
sampling, to detect widespread subclinical wild virus infections,
signaling the need to mobilize further control measures.
At the final stage, a critical line of evidence for certification
of eradication of indigenous wild polioviruses will be the
consistent inability to detect their presence in either clinical
or environmental specimens (10).
4.3.3. Research needs,
In spite of important progress in environmental sampling and
analysis, several technical problems are yet to be solved and
lo
further research is needed.
a) An important research need is how to demonstrate the presence
of a small proportion of polioviruses among other enteroviruses,
and especially how to detect a minority of wild-type viruses
among OPV strains. The existence of small amounts of wild
polioviruses in specimens containing relatively high
concentrations of vaccine viruses cannot be excluded so far (4).
PCR may be a successful approach to this problem. However, a
disadvantage of this method is that it must be known in advance
what poliovirus genotypes are being sought (27).
b) Several sampling methods for polioviruses in sewage are
currently in use. Sampling site, sampling method (grab or
continuous), sample size, and sampling frequency should be
standardized. Duration of environmental surveillance needed after
global disappearance of clinical cases should also be considered
(2) .
c) The environmental surveillance methods should be adaptable to
different local situations. For example, many cities in the
developing countries do not have sewage system. Sampling latrines
may be an alternative, although it is more complicated.
Furthermore, it may prove unreliable, since infants often don't
use them.
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5. CONCLUSION.
Many problems remain before poliomyelitis global eradication can
be accomplished and it is unlikely that the aim will be reached
before the year 2000 or even 2010.
The main remaining impediment is probably the difficulty for some
developing countries in ridding poliomyelitis endemicity by
reaching a high level of OPV immunization coverage. Obstacles are
numerous, involving insufficient health budget, lack of political
will, draining of resources by recent major public health
problems (cholera epidemic, sexually transmitted diseases, AIDS
pandemic), undeveloped health-care systems, untrained personnel,
and persistence of conflict zones (wars) in some parts of the
world.
Primary health-care systems are improving quite slowly in
several developing countries. However, this basic health system
is the best type of health service to take over and maintain the
high immunization coverage levels achieved, for example in the
Americas, by the campaign immunization strategies. Time and
resources will be needed to reinforce these primary health-care
systems in developing countries.
Two other important impediments are associated with the
surveillance of poliomyelitis.
a) The disease is still underreported from several
countries/areas and laboratory-based diagnosis of poliomyelitis
is not yet available troughouth the world. The causes mentioned
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for insufficient immunization coverage levels contribute to this
insufficient surveillance system.
b) The second objective of the global poliomyelitis eradication
initiative is to achieve no wild poliovirus identified worldwide
through sampling of communities and the environment (1). Despite
the important progress accomplished in environmental poliovirus
sampling and identification, further research is needed to
standardize and to increase the sensitivity of these methods. A
very high of sensivity in identifying wild-type poliovirus
circulation has to be reached, since it will not be possible to
prove the absence of wild-type poliovirus in the environment but
only to estimate the probability of the absence of the wild-type
poliovirus.
Considering the importance of these remaining problems, it is
likely that a long-term program involving activities of research,
surveillance and implementation of immunization, planned on a
period of 30 to 40 years, will be necessary before poliomyelitis
global eradication can be accomplished.
Finally, it is important to emphasize that the eradication
initiative must remain integrated with primary health care in
order to maintain its role of leader in the improvement of basic
health services.
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